A Study of HS-10382 in Patients With Chronic Myeloid Leukemia.

Summary

HS-10382 is a small molecular, oral potent, allosteric inhibitor. By binding a myristoyl site of the BCR-ABL1 protein, HS-10382 locks BCR-ABL1 into an inactive conformation. The purpose of this study is to investigate the safety/tolerability and the pharmacokinetic(PK) profile of HS-10382 in patients with chronic myeloid leukemia (CML). Anti-CML activity will also be investigated in this study.

Timeline

Start

2022-04-28

Primary completion

2024-12-30

Completion

2026-09-30

Drugs

Indications